MovDisordV3, Main, Curation, bibRecord, 002869

Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease

Identifieur interne : 002869 ( Main/Curation ); précédent : 002868; suivant : 002870

Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease

Auteurs : Thomas Müller [Allemagne] ; Dirk Woitalla [Allemagne] ; Oliver Goetze [Allemagne, Suisse] ; Christoph Erdmann [Allemagne]

Source :

Movement Disorders [ 0885-3185 ] ; 2008-07-30.

RBID : ISTEX:A6B9BF2A4B17E76BA549BDD0BF27D734BF8610B6

Descripteurs français

Pascal (Inist)
- Entacapone, Homme, Lévodopa, Maladie de Parkinson, Pathologie du système nerveux.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Adult, Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (pharmacokinetics), Antiparkinson Agents (therapeutic use), Breath Tests, Caprylates (administration & dosage), Caprylates (pharmacokinetics), Carbidopa (administration & dosage), Carbidopa (pharmacokinetics), Carbidopa (therapeutic use), Carbon Isotopes (analysis), Catechol O-Methyltransferase Inhibitors, Catechols (pharmacology), Drug Interactions, Drug Therapy, Combination, Entacapone, Enzyme Inhibitors (pharmacology), Female, Gastric Emptying (drug effects), Human, Humans, Intestinal Absorption (drug effects), Levodopa, Levodopa (administration & dosage), Levodopa (pharmacokinetics), Levodopa (therapeutic use), Male, Middle Aged, Nervous system diseases, Nitriles (pharmacology), Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Parkinson disease, Parkinson's disease, Solubility, absorption, entacapone, levodopa.
MESH :
- chemical , administration & dosage : Antiparkinson Agents, Caprylates, Carbidopa, Levodopa.
- chemical , analysis : Carbon Isotopes.
- chemical , pharmacokinetics : Antiparkinson Agents, Caprylates, Carbidopa, Levodopa.
- chemical , pharmacology : Catechols, Enzyme Inhibitors, Nitriles.
- chemical , therapeutic use : Antiparkinson Agents, Carbidopa, Levodopa.
- drug effects : Gastric Emptying, Intestinal Absorption.
- drug therapy : Parkinson Disease.
- metabolism : Parkinson Disease.
- Adult, Aged, Breath Tests, Catechol O-Methyltransferase Inhibitors, Drug Interactions, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Solubility.

Abstract

Entacapone (EN) improves the efficacy of levodopa/dopadecarboxylase inhibitor (LD/DDI) formulations by inhibition of the enzyme catechol‐O‐methyltransferase (COMT). COMT inhibition also promotes the synthesis of basic LD metabolites, whereas DDI support the composition of acidic LD derivatives. LD metabolism correlates to the one of 13C‐sodium‐octanoate, which is employed in breath tests to measure gastric emptying velocity. Objectives were to investigate the impact of COMT inhibition on the recovery rate of 13C‐sodium‐octanoate in parkinsonian patients, who received first 100 mg LD/Carbidopa (CD) and the next day 100 mg LD/CD/EN combined with 13C‐sodium‐octanoate in each case. The recovery rate of 13C‐sodium‐octanoate was significant higher during the LD/CD/EN–compared with the LD/CD condition. COMT inhibition combined with LD/DDI improves absorption of a co‐administered salt probably due to a COMT inhibition induced basic environment in gastrointestinal membranes. This improves dissolution and absorption of acids and salts. Thus it may enhance absorption of LD itself. © 2008 Movement Disorder Society

Url:

https://api.istex.fr/document/A6B9BF2A4B17E76BA549BDD0BF27D734BF8610B6/fulltext/pdf

DOI: 10.1002/mds.22176

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000E01
to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :000E01
to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001425
to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002186
to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :002186
to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002311
to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :002177
to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :002177
to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002177
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003447
to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001160
to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :001B59
to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001266
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003874

Links to Exploration step

ISTEX:A6B9BF2A4B17E76BA549BDD0BF27D734BF8610B6

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease</title>
<author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name>
</author>
<author><name sortKey="Woitalla, Dirk" sort="Woitalla, Dirk" uniqKey="Woitalla D" first="Dirk" last="Woitalla">Dirk Woitalla</name>
</author>
<author><name sortKey="Goetze, Oliver" sort="Goetze, Oliver" uniqKey="Goetze O" first="Oliver" last="Goetze">Oliver Goetze</name>
</author>
<author><name sortKey="Erdmann, Christoph" sort="Erdmann, Christoph" uniqKey="Erdmann C" first="Christoph" last="Erdmann">Christoph Erdmann</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:A6B9BF2A4B17E76BA549BDD0BF27D734BF8610B6</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1002/mds.22176</idno>
<idno type="url">https://api.istex.fr/document/A6B9BF2A4B17E76BA549BDD0BF27D734BF8610B6/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000E01</idno>
<idno type="wicri:Area/Istex/Curation">000E01</idno>
<idno type="wicri:Area/Istex/Checkpoint">001425</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Muller T:entacapone:improves:absorption</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:18546331</idno>
<idno type="wicri:Area/PubMed/Corpus">002186</idno>
<idno type="wicri:Area/PubMed/Curation">002186</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002311</idno>
<idno type="wicri:Area/Ncbi/Merge">002177</idno>
<idno type="wicri:Area/Ncbi/Curation">002177</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002177</idno>
<idno type="wicri:Area/Main/Merge">003447</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:08-0417086</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001160</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001B59</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001266</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Muller T:entacapone:improves:absorption</idno>
<idno type="wicri:Area/Main/Merge">003874</idno>
<idno type="wicri:Area/Main/Curation">002869</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease</title>
<author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, St. Joseph Hospital Berlin‐Weißensee, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum</wicri:regionArea>
<wicri:noRegion>Bochum</wicri:noRegion>
<wicri:noRegion>Bochum</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Woitalla, Dirk" sort="Woitalla, Dirk" uniqKey="Woitalla D" first="Dirk" last="Woitalla">Dirk Woitalla</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum</wicri:regionArea>
<wicri:noRegion>Bochum</wicri:noRegion>
<wicri:noRegion>Bochum</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Goetze, Oliver" sort="Goetze, Oliver" uniqKey="Goetze O" first="Oliver" last="Goetze">Oliver Goetze</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Medicine I, St. Josef Hospital, Ruhr‐University Bochum, Bochum</wicri:regionArea>
<wicri:noRegion>Bochum</wicri:noRegion>
<wicri:noRegion>Bochum</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">Suisse</country>
<wicri:regionArea>University Hospital Zurich, Division of Gastroenterology and Hepatology, Zürich</wicri:regionArea>
<placeName><settlement type="city">Zurich</settlement>
<region nuts="3" type="region">Canton de Zurich</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Erdmann, Christoph" sort="Erdmann, Christoph" uniqKey="Erdmann C" first="Christoph" last="Erdmann">Christoph Erdmann</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum</wicri:regionArea>
<wicri:noRegion>Bochum</wicri:noRegion>
<wicri:noRegion>Bochum</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2008-07-30">2008-07-30</date>
<biblScope unit="vol">23</biblScope>
<biblScope unit="issue">10</biblScope>
<biblScope unit="page" from="1458">1458</biblScope>
<biblScope unit="page" to="1461">1461</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">A6B9BF2A4B17E76BA549BDD0BF27D734BF8610B6</idno>
<idno type="DOI">10.1002/mds.22176</idno>
<idno type="ArticleID">MDS22176</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Antiparkinson Agents (pharmacokinetics)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Breath Tests</term>
<term>Caprylates (administration & dosage)</term>
<term>Caprylates (pharmacokinetics)</term>
<term>Carbidopa (administration & dosage)</term>
<term>Carbidopa (pharmacokinetics)</term>
<term>Carbidopa (therapeutic use)</term>
<term>Carbon Isotopes (analysis)</term>
<term>Catechol O-Methyltransferase Inhibitors</term>
<term>Catechols (pharmacology)</term>
<term>Drug Interactions</term>
<term>Drug Therapy, Combination</term>
<term>Entacapone</term>
<term>Enzyme Inhibitors (pharmacology)</term>
<term>Female</term>
<term>Gastric Emptying (drug effects)</term>
<term>Human</term>
<term>Humans</term>
<term>Intestinal Absorption (drug effects)</term>
<term>Levodopa</term>
<term>Levodopa (administration & dosage)</term>
<term>Levodopa (pharmacokinetics)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Nitriles (pharmacology)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Solubility</term>
<term>absorption</term>
<term>entacapone</term>
<term>levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Caprylates</term>
<term>Carbidopa</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Carbon Isotopes</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Caprylates</term>
<term>Carbidopa</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Catechols</term>
<term>Enzyme Inhibitors</term>
<term>Nitriles</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Carbidopa</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Gastric Emptying</term>
<term>Intestinal Absorption</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Breath Tests</term>
<term>Catechol O-Methyltransferase Inhibitors</term>
<term>Drug Interactions</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Solubility</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Entacapone</term>
<term>Homme</term>
<term>Lévodopa</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Entacapone (EN) improves the efficacy of levodopa/dopadecarboxylase inhibitor (LD/DDI) formulations by inhibition of the enzyme catechol‐O‐methyltransferase (COMT). COMT inhibition also promotes the synthesis of basic LD metabolites, whereas DDI support the composition of acidic LD derivatives. LD metabolism correlates to the one of 13C‐sodium‐octanoate, which is employed in breath tests to measure gastric emptying velocity. Objectives were to investigate the impact of COMT inhibition on the recovery rate of 13C‐sodium‐octanoate in parkinsonian patients, who received first 100 mg LD/Carbidopa (CD) and the next day 100 mg LD/CD/EN combined with 13C‐sodium‐octanoate in each case. The recovery rate of 13C‐sodium‐octanoate was significant higher during the LD/CD/EN–compared with the LD/CD condition. COMT inhibition combined with LD/DDI improves absorption of a co‐administered salt probably due to a COMT inhibition induced basic environment in gastrointestinal membranes. This improves dissolution and absorption of acids and salts. Thus it may enhance absorption of LD itself. © 2008 Movement Disorder Society</div>
</front>
</TEI>
<double idat="0885-3185:2008:Muller T:entacapone:improves:absorption"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Entacapone Improves Absorption of a Coadministered Salt in Patients with Parkinson's Disease</title>
<author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neurology, St. Joseph Hospital Berlin-Weissensee</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, St. Josef Hospital, Ruhr University Bochum</s1>
<s2>Bochum</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Bochum</wicri:noRegion>
<wicri:noRegion>Ruhr University Bochum</wicri:noRegion>
<wicri:noRegion>Bochum</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Woitalla, Dirk" sort="Woitalla, Dirk" uniqKey="Woitalla D" first="Dirk" last="Woitalla">Dirk Woitalla</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, St. Josef Hospital, Ruhr University Bochum</s1>
<s2>Bochum</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Bochum</wicri:noRegion>
<wicri:noRegion>Ruhr University Bochum</wicri:noRegion>
<wicri:noRegion>Bochum</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Goetze, Oliver" sort="Goetze, Oliver" uniqKey="Goetze O" first="Oliver" last="Goetze">Oliver Goetze</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Medicine 1, St. Josef Hospital, Ruhr-University Bochum</s1>
<s2>Bochum</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Bochum</wicri:noRegion>
<wicri:noRegion>Ruhr-University Bochum</wicri:noRegion>
<wicri:noRegion>Bochum</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>University Hospital Zurich, Division of Gastroenterology and Hepatology</s1>
<s2>Zürich</s2>
<s3>CHE</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
<placeName><settlement type="city">Zurich</settlement>
<region nuts="3" type="region">Canton de Zurich</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Erdmann, Christoph" sort="Erdmann, Christoph" uniqKey="Erdmann C" first="Christoph" last="Erdmann">Christoph Erdmann</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, St. Josef Hospital, Ruhr University Bochum</s1>
<s2>Bochum</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Bochum</wicri:noRegion>
<wicri:noRegion>Ruhr University Bochum</wicri:noRegion>
<wicri:noRegion>Bochum</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0417086</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0417086 INIST</idno>
<idno type="RBID">Pascal:08-0417086</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001160</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001B59</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001266</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Muller T:entacapone:improves:absorption</idno>
<idno type="wicri:Area/Main/Merge">003874</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Entacapone Improves Absorption of a Coadministered Salt in Patients with Parkinson's Disease</title>
<author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neurology, St. Joseph Hospital Berlin-Weissensee</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, St. Josef Hospital, Ruhr University Bochum</s1>
<s2>Bochum</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Bochum</wicri:noRegion>
<wicri:noRegion>Ruhr University Bochum</wicri:noRegion>
<wicri:noRegion>Bochum</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Woitalla, Dirk" sort="Woitalla, Dirk" uniqKey="Woitalla D" first="Dirk" last="Woitalla">Dirk Woitalla</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, St. Josef Hospital, Ruhr University Bochum</s1>
<s2>Bochum</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Bochum</wicri:noRegion>
<wicri:noRegion>Ruhr University Bochum</wicri:noRegion>
<wicri:noRegion>Bochum</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Goetze, Oliver" sort="Goetze, Oliver" uniqKey="Goetze O" first="Oliver" last="Goetze">Oliver Goetze</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Medicine 1, St. Josef Hospital, Ruhr-University Bochum</s1>
<s2>Bochum</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Bochum</wicri:noRegion>
<wicri:noRegion>Ruhr-University Bochum</wicri:noRegion>
<wicri:noRegion>Bochum</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>University Hospital Zurich, Division of Gastroenterology and Hepatology</s1>
<s2>Zürich</s2>
<s3>CHE</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
<placeName><settlement type="city">Zurich</settlement>
<region nuts="3" type="region">Canton de Zurich</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Erdmann, Christoph" sort="Erdmann, Christoph" uniqKey="Erdmann C" first="Christoph" last="Erdmann">Christoph Erdmann</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, St. Josef Hospital, Ruhr University Bochum</s1>
<s2>Bochum</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Bochum</wicri:noRegion>
<wicri:noRegion>Ruhr University Bochum</wicri:noRegion>
<wicri:noRegion>Bochum</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Entacapone</term>
<term>Human</term>
<term>Levodopa</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Entacapone</term>
<term>Homme</term>
<term>Lévodopa</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Entacapone (EN) improves the efficacy of levodopa/dopadecarboxylase inhibitor (LD/DDI) formulations by inhibition of the enzyme catechol-O-methyltransferase (COMT). COMT inhibition also promotes the synthesis of basic LD metabolites, whereas DDI support the composition of acidic LD derivatives. LD metabolism correlates to the one of <sup>13</sup>
C-sodium-octanoate, which is employed in breath tests to measure gastric emptying velocity. Objectives were to investigate the impact of COMT inhibition on the recovery rate of <sup>13</sup>
C-sodium-octanoate in parkinsonian patients, who received first 100 mg LD/Carbidopa (CD) and the next day 100 mg LD/CD/EN combined with <sup>13</sup>
C-sodium-octanoate in each case. The recovery rate of <sup>13</sup>
C-sodium-octanoate was significant higher during the LD/CD/EN-compared with the LD/CD condition. COMT inhibition combined with LD/DDI improves absorption of a co-administered salt probably due to a COMT inhibition induced basic environment in gastrointestinal membranes. This improves dissolution and absorption of acids and salts. Thus it may enhance absorption of LD itself.</div>
</front>
</TEI>
</INIST>
<ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease</title>
<author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name>
</author>
<author><name sortKey="Woitalla, Dirk" sort="Woitalla, Dirk" uniqKey="Woitalla D" first="Dirk" last="Woitalla">Dirk Woitalla</name>
</author>
<author><name sortKey="Goetze, Oliver" sort="Goetze, Oliver" uniqKey="Goetze O" first="Oliver" last="Goetze">Oliver Goetze</name>
</author>
<author><name sortKey="Erdmann, Christoph" sort="Erdmann, Christoph" uniqKey="Erdmann C" first="Christoph" last="Erdmann">Christoph Erdmann</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:A6B9BF2A4B17E76BA549BDD0BF27D734BF8610B6</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1002/mds.22176</idno>
<idno type="url">https://api.istex.fr/document/A6B9BF2A4B17E76BA549BDD0BF27D734BF8610B6/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000E01</idno>
<idno type="wicri:Area/Istex/Curation">000E01</idno>
<idno type="wicri:Area/Istex/Checkpoint">001425</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Muller T:entacapone:improves:absorption</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:18546331</idno>
<idno type="wicri:Area/PubMed/Corpus">002186</idno>
<idno type="wicri:Area/PubMed/Curation">002186</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002311</idno>
<idno type="wicri:Area/Ncbi/Merge">002177</idno>
<idno type="wicri:Area/Ncbi/Curation">002177</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002177</idno>
<idno type="wicri:Area/Main/Merge">003447</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease</title>
<author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, St. Joseph Hospital Berlin‐Weißensee, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum</wicri:regionArea>
<wicri:noRegion>Bochum</wicri:noRegion>
<wicri:noRegion>Bochum</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Woitalla, Dirk" sort="Woitalla, Dirk" uniqKey="Woitalla D" first="Dirk" last="Woitalla">Dirk Woitalla</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum</wicri:regionArea>
<wicri:noRegion>Bochum</wicri:noRegion>
<wicri:noRegion>Bochum</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Goetze, Oliver" sort="Goetze, Oliver" uniqKey="Goetze O" first="Oliver" last="Goetze">Oliver Goetze</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Medicine I, St. Josef Hospital, Ruhr‐University Bochum, Bochum</wicri:regionArea>
<wicri:noRegion>Bochum</wicri:noRegion>
<wicri:noRegion>Bochum</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">Suisse</country>
<wicri:regionArea>University Hospital Zurich, Division of Gastroenterology and Hepatology, Zürich</wicri:regionArea>
<placeName><settlement type="city">Zurich</settlement>
<region nuts="3" type="region">Canton de Zurich</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Erdmann, Christoph" sort="Erdmann, Christoph" uniqKey="Erdmann C" first="Christoph" last="Erdmann">Christoph Erdmann</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum</wicri:regionArea>
<wicri:noRegion>Bochum</wicri:noRegion>
<wicri:noRegion>Bochum</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2008-07-30">2008-07-30</date>
<biblScope unit="vol">23</biblScope>
<biblScope unit="issue">10</biblScope>
<biblScope unit="page" from="1458">1458</biblScope>
<biblScope unit="page" to="1461">1461</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">A6B9BF2A4B17E76BA549BDD0BF27D734BF8610B6</idno>
<idno type="DOI">10.1002/mds.22176</idno>
<idno type="ArticleID">MDS22176</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Antiparkinson Agents (pharmacokinetics)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Breath Tests</term>
<term>Caprylates (administration & dosage)</term>
<term>Caprylates (pharmacokinetics)</term>
<term>Carbidopa (administration & dosage)</term>
<term>Carbidopa (pharmacokinetics)</term>
<term>Carbidopa (therapeutic use)</term>
<term>Carbon Isotopes (analysis)</term>
<term>Catechol O-Methyltransferase Inhibitors</term>
<term>Catechols (pharmacology)</term>
<term>Drug Interactions</term>
<term>Drug Therapy, Combination</term>
<term>Enzyme Inhibitors (pharmacology)</term>
<term>Female</term>
<term>Gastric Emptying (drug effects)</term>
<term>Humans</term>
<term>Intestinal Absorption (drug effects)</term>
<term>Levodopa (administration & dosage)</term>
<term>Levodopa (pharmacokinetics)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nitriles (pharmacology)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson's disease</term>
<term>Solubility</term>
<term>absorption</term>
<term>entacapone</term>
<term>levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Caprylates</term>
<term>Carbidopa</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Carbon Isotopes</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Caprylates</term>
<term>Carbidopa</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Catechols</term>
<term>Enzyme Inhibitors</term>
<term>Nitriles</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Carbidopa</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Gastric Emptying</term>
<term>Intestinal Absorption</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Breath Tests</term>
<term>Catechol O-Methyltransferase Inhibitors</term>
<term>Drug Interactions</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Solubility</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Entacapone (EN) improves the efficacy of levodopa/dopadecarboxylase inhibitor (LD/DDI) formulations by inhibition of the enzyme catechol‐O‐methyltransferase (COMT). COMT inhibition also promotes the synthesis of basic LD metabolites, whereas DDI support the composition of acidic LD derivatives. LD metabolism correlates to the one of 13C‐sodium‐octanoate, which is employed in breath tests to measure gastric emptying velocity. Objectives were to investigate the impact of COMT inhibition on the recovery rate of 13C‐sodium‐octanoate in parkinsonian patients, who received first 100 mg LD/Carbidopa (CD) and the next day 100 mg LD/CD/EN combined with 13C‐sodium‐octanoate in each case. The recovery rate of 13C‐sodium‐octanoate was significant higher during the LD/CD/EN–compared with the LD/CD condition. COMT inhibition combined with LD/DDI improves absorption of a co‐administered salt probably due to a COMT inhibition induced basic environment in gastrointestinal membranes. This improves dissolution and absorption of acids and salts. Thus it may enhance absorption of LD itself. © 2008 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
</double>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002869 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 002869 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Curation
   |type=    RBID
   |clé=     ISTEX:A6B9BF2A4B17E76BA549BDD0BF27D734BF8610B6
   |texte=   Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease

Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri